Nu-Med Plus, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 16, 2020 at 03:15 pm EST
Share
Nu-Med Plus, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 449,758 compared to USD 146,213 a year ago. Net loss was USD 453,824 compared to USD 150,576 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to Basic EPS - Continuing Operations of USD 0 a year ago. For the nine months, operating loss was USD 1.503 million compared to USD 813,726 a year ago. Net loss was USD 1.515 million compared to USD 826,955 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.
Nu-Med Plus, Inc. is a medical device company, which is principally engaged in the designing, development, enhancement and commercialization of later-stage medical devices. The Company is focused on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide (NO) delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers high purity NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery provides a range of concentrations and flow rates of NO.
NU-MED PLUS, INC. 
